Recently, Shardul Thakur’s signing with the Lucknow Super Giants (LSG) has raised eyebrows regarding its implications for the Indian national cricket team during the critical English summer. This ...

Shardul Thakur's recent signing with the Lucknow Super Giants (LSG) in the IPL raises questions about the potential impact on his standing within the Indian Test cricket team, especially with the ...

Shardul Thakur went unsold in November’s IPL auction for the 2025 season. But just when his hopes of playing in the league this season seemed out of sight, Lucknow Super Giants roped in the ...

Essex director of cricket Chris Silverwood says they are actively seeking a replacement for Shardul Thakur after the India pace bowler pulled out of a deal to join the club. The 33-year-old will ...

IPL 2025: Team India’s experienced fast bowling all-rounder Shardul Thakur joins Lucknow Super Giants (LSG) as a replacement for left-arm fast bowler Mohsin Khan, according to ESPNcricinfo. Shardul ...

India all-rounder Shardul Thakur has replaced the injured Mohsin Khan at Lucknow Super Giants in the Indian Premier League (IPL). Left-arm seamer Mohsin, 26, has been ruled out of the tournament ...

On that note, let us look at why LSG signing Shardul Thakur as a replacement player for IPL 2025 would be the right move: Shardul Thakur could play a flexible role for LSG. While his numbers in ...

Bitcoin has already has plunged more than 20% from its record high two months ago, but the fall may not be over yet, according to analysts. The largest crypto BTCUSD traded at around $84,353 ...

IMAGE: Shardul Thakur was released by the Chennai Super Kings last season after picking just 5 wickets in 9 outings. Photograph: BCCI Shardul Thakur, who went unsold at the IPL mega auction ...

That’s often less than what merchants pay for credit card processing. The SPY Token and Why It Matters The SPY token powers everything in the SpacePay system. With a total supply of 34 billion ...

He thinks now is the perfect time for investors to deliver a bit of ‘portfolio medicine ... that’s one of the reasons why it hasn’t run away,” Woods said. “But they’re going to start producing some ...